Ads
related to: ucla breast cancer- Adverse Reaction Data
View Common Adverse Reactions
& A Guide For Managing Them.
- Dosing & Administration
See Dosing Regimen & Preparation
Info For A New Treatment Option
- Research Design & Data
Discover Eligibility Criteria &
Baseline Patient Characteristics.
- Request A Representative
Get More Info About A Now Approved
Treatment Option For HR+ HER2- mBC.
- Adverse Reaction Data
Search results
Results From The WOW.Com Content Network
Dennis Joseph Slamon (born August 6, 1948), [1] [2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA.He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.
Love was a clinical professor of surgery at the David Geffen School of Medicine at UCLA. Love also served as the Founder and Medical Director of the Dr. Susan Love Foundation for Breast Cancer Research, formerly titled The Santa Barbara Breast Cancer Institute. In 2020, Love became the Chief Visionary Officer.
“That was quite revolutionary at the time,” said Dr. Patricia Ganz, a UCLA breast cancer oncologist and director of the Center for Cancer Prevention and Control Research at the Jonsson ...
Slamon is a physician scientist at UCLA Medical Center (Los Angeles), where he has developed the experimental drug Herceptin, which he believes will become a treatment for breast cancer. However, when the drug company stops funding the research, philanthropists, including Lilly Tartikoff (Angie Harmon) and Ronald Perelman help him continue drug ...
For premium support please call: 800-290-4726 more ways to reach us
Breast cancer, lung cancer and colon cancer are solid cancer tumors known as carcinomas, ... a medical oncologist and hematologist at UCLA Health, who is now part of Doucette’s treatment team ...